Chronic inflammatory diseases are associated with accelerated atherosclerosis. Psoriasis in particular accelerates the formation of high risk coronary plaque which drives heart attack and stroke. Providers and patients need to be aware of these associations.

In this interview, Nehal N. Mehta, MD MSCE and W. Douglas Weaver MD, MACC, with Matt A. Cavender MD, MPH, FACC, discuss Inflamed! Populations at Risk for Inflammation Associated CVD.

Which changes to the ACC/AHA/SCAI Coronary Artery Revascularization Guidelines will have the greatest impact to the patient? Which of the published “Top Ten Take-Away Messages” is most important?

In this interview, Jacqueline E. Tamis-Holland, MD, FACC, FAHA, FSCAI and Roxana Mehran MD, FACC, with Yuvraj Chowdhury MD, discuss Most Significant Changes from the Prior Coronary Artery Revascularization Guidelines.

What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?

In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.

Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS and Nanette Kass Wenger MD, MACC, discuss ACC.22 Late Breaker: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT.

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.

This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.

In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Clinicians often recommend dietary sodium reduction for almost all their patients with HF. Whether or not this practice should continue remains an uncertain question in almost every clinic visit. We spend a fair amount of time counselling patients on this, and patients want to know if they need to undertake a full change in their diet to improve how they feel or function, and if this changes will increase or decrease the chance of being in the hospital again.

In this interview, Justin A. Ezekowitz, MBBCh, MSc and Steven E. Nissen MD, MACC, with Yuvraj Chowdhury MD, discuss Late Breaker: SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure.

Heart failure patients experience exercise intolerance and functional limitation every day. While the targeting of functional capacity is an important unmet need, this study found that the change in peak oxygen uptake did not differ between patients taking omecamtiv mecarbil and placebo.

How do current guideline-directed medical therapies for heart failure impact exercise capacity? How does omecamtive mecarbil differ from other heart failure pharmacotherapies?

In this interview, Gregory Lewis, MD and Jeroen J. Bax PhD, MD, FACC, with Ioannis Mastoris, MD, MPHcand, discuss Late Breaker: METEORIC-HF: The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic HFrEF.

Heart failure patients are generally multi-morbid and at risk for hyperkalemia, which makes treatment with life-saving therapies like RAASi difficult and leads to compromised medical treatment and in turn poor outcomes. This trials showed that with the use of patiromer, one can simultaneously lower the risk of hyperkalemia and increase optimal medical therapy for heart failure with reduced ejection fraction.

In this interview, Javed Butler, MD MPH MBA, Anthony N. DeMaria MD, MACC, with Ioannis Mastoris, MD, MPHcand, discuss the Late Breaker: DIAMOND trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction.